Research programme: small molecule therapeutics - Curve Therapeutics/Merck Sharp & Dohme
Latest Information Update: 21 Feb 2022
At a glance
- Originator Curve Therapeutics; Merck Sharp & Dohme
- Developer Merck Sharp & Dohme
- Class Antineoplastics; Small molecules
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Research Cancer; Neurological disorders